UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome

Neuropharmacology, 1999-12, Vol.38 (12), p.1917-1920

1999

Link zum Volltext

Verfügbarkeit prüfen

Understanding mental retardation in Down's syndrome using trisomy 16 mouse models

Genes, brain and behavior, 2003-06, Vol.2 (3), p.167-178

2003

Link zum Volltext

Verfügbarkeit prüfen

Altered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome

Neuropharmacology, 1997-11, Vol.36 (11), p.1549-1554

1997

Link zum Volltext

Verfügbarkeit prüfen

Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome

Neuropharmacology, 2005-07, Vol.49 (1), p.122-128

2005

Link zum Volltext

Verfügbarkeit prüfen

5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat

Neuropharmacology, 2004-03, Vol.46 (4), p.504-510

2004

Link zum Volltext

Verfügbarkeit prüfen

Ts65Dn mouse, a Down syndrome model, exhibits elevated myo-Inositol in selected brain regions and peripheral tissues

Neurochemical research, 2000-04, Vol.25 (4), p.431-435

2000

Link zum Volltext

Verfügbarkeit prüfen

Responses to NMDA in cultured hippocampal neurons from trisomy 16 embryonic mice

Neuroscience letters, 1997-09, Vol.232 (3), p.131-134

1997

Link zum Volltext

Verfügbarkeit prüfen

Chronic dihydropyridine treatment can reverse the behavioural consequences of and prevent adaptations to, chronic ethanol treatment

British journal of pharmacology, 1991-07, Vol.103 (3), p.1669-1676

1991

Link zum Volltext

Verfügbarkeit prüfen

Effect of 6‐cyano‐2,3‐dihydroxy‐7‐nitro‐quinoxaline (CNQX) on dorsal root‐, NMDA‐, kainate‐ and quisqualate‐mediated depolarization of rat motoneurones in vitro

British journal of pharmacology, 1990-08, Vol.100 (4), p.850-854

1990

Link zum Volltext

Verfügbarkeit prüfen

Increased expression of NR2A subunit does not alter NMDA‐evoked responses in cultured fetal trisomy 16 mouse hippocampal neurons

Journal of neurochemistry, 2001-03, Vol.76 (6), p.1663-1669

2001

Link zum Volltext

Verfügbarkeit prüfen

Serotoninergic modulation of excitability in area CA1 of the in vitro rat hippocampus

Neuroscience letters, 1995-10, Vol.199 (3), p.211-214

1995

Link zum Volltext

Verfügbarkeit prüfen

Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: A model of Down syndrome

Journal of comparative neurology (1911), 2006-02, Vol.494 (5), p.815-833

2006

Link zum Volltext

Verfügbarkeit prüfen

Nitrendipine decreases benzodiazepine withdrawal seizures but not the development of benzodiazepine tolerance or withdrawal signs

British journal of pharmacology, 1990-11, Vol.101 (3), p.691-697

1990

Link zum Volltext

Verfügbarkeit prüfen

The effect of centrally acting myorelaxants on NMDA receptor‐mediated synaptic transmission in the immature rat spinal cord in vitro

British journal of pharmacology, 1992-10, Vol.107 (2), p.628-633

1992

Link zum Volltext

Verfügbarkeit prüfen

The effects of central myorelaxants on synaptically‐evoked primary afferent depolarization in the immature rat spinal cord in vitro

British journal of pharmacology, 1994-02, Vol.111 (2), p.497-502

1994

Link zum Volltext

Verfügbarkeit prüfen

The role of 5-HT2A receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro

European journal of pharmacology, 2005-09, Vol.520 (1-3), p.77-85

2005

Link zum Volltext

Verfügbarkeit prüfen

Potentiation of synaptic reflexes by D-serine in the rat spinal cord in vitro

European journal of pharmacology, 1991-03, Vol.195 (2), p.241-244

1991

Link zum Volltext

Verfügbarkeit prüfen

On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models

Brain Research Reviews, 2001-04, Vol.35 (2), p.115-145

2001

Link zum Volltext

Verfügbarkeit prüfen

5-HT 2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat

Neuropharmacology, 2004, Vol.46 (4), p.504-510

2004

Link zum Volltext

Verfügbarkeit prüfen

5-HT sub(2) receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat

Neuropharmacology, 2004-03, Vol.46 (4), p.504-510

2004

Link zum Volltext

Verfügbarkeit prüfen

SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacology

European neuropsychopharmacology, 2002-10, Vol.12, p.277-277

2002

Link zum Volltext

Verfügbarkeit prüfen

Potentiation of spinal synaptic transmission in vitro by D-serine in the presence of CNQX

European journal of pharmacology, 1990-07, Vol.183 (5), p.1667-1667

1990

Link zum Volltext

Verfügbarkeit prüfen

Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1

Nature (London), 2009-06, Vol.459 (7250), p.1126-1130

2009

Link zum Volltext

Verfügbarkeit prüfen

Down syndrome suppression of tumor growth and the role of the calcineurin inhibitor DSCR1

Nature (London), 2009-05, Vol.459 (7250), p.1126-1130

2009

Link zum Volltext

Verfügbarkeit prüfen

The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro

European journal of pharmacology, 2005-09, Vol.520 (1-3), p.77-85

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 25

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome

Understanding mental retardation in Down's syndrome using trisomy 16 mouse models

Altered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome

Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome

5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat

Ts65Dn mouse, a Down syndrome model, exhibits elevated myo-Inositol in selected brain regions and peripheral tissues

Responses to NMDA in cultured hippocampal neurons from trisomy 16 embryonic mice

Chronic dihydropyridine treatment can reverse the behavioural consequences of and prevent adaptations to, chronic ethanol treatment

Effect of 6‐cyano‐2,3‐dihydroxy‐7‐nitro‐quinoxaline (CNQX) on dorsal root‐, NMDA‐, kainate‐ and quisqualate‐mediated depolarization of rat motoneurones in vitro

Increased expression of NR2A subunit does not alter NMDA‐evoked responses in cultured fetal trisomy 16 mouse hippocampal neurons

Serotoninergic modulation of excitability in area CA1 of the in vitro rat hippocampus

Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: A model of Down syndrome

Nitrendipine decreases benzodiazepine withdrawal seizures but not the development of benzodiazepine tolerance or withdrawal signs

The effect of centrally acting myorelaxants on NMDA receptor‐mediated synaptic transmission in the immature rat spinal cord in vitro

The effects of central myorelaxants on synaptically‐evoked primary afferent depolarization in the immature rat spinal cord in vitro

The role of 5-HT2A receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro

Potentiation of synaptic reflexes by D-serine in the rat spinal cord in vitro

On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models

5-HT 2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat

5-HT sub(2) receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat

SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacology

Potentiation of spinal synaptic transmission in vitro by D-serine in the presence of CNQX

Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1

Down syndrome suppression of tumor growth and the role of the calcineurin inhibitor DSCR1

The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro

Suchergebnisse filtern